Company / SG&A Expense
IONIS PHARMACEUTICALS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$393.9M
FY2025
5-year range
$150.3M / $393.9M
FY2021-FY2025
Trend
+47.3%
vs FY2024
Sector context
#45 of 213
Health Care
What the data says
IONIS PHARMACEUTICALS INC's sg&a expense of $394M is higher than 79% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 3 consecutive years, from $150M in FY2022 to $394M in FY2025.
Based on SEC 10-K filings.
$394M in FY2025 with a 5-year CAGR of +10.0%. Top quartile in the Health Care sector.
Increased from $233M to $394M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +37.9%
- 5-Year CAGR
- +10.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 213This company $393.9M Sector average $722.3M
▼
-45.5% below sector average
Key checks
Key Insights
- IONIS PHARMACEUTICALS INC's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +10.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 47.3% year-over-year.
- Ranks #45 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $393.9M | +47.3% |
| FY2024 | $267.5M | +15.0% |
| FY2023 | $232.6M | +54.8% |
| FY2022 | $150.3M | -47.6% |
| FY2021 | $286.6M | +17.2% |
| FY2020 | $244.6M | +125.5% |
| FY2019 | $108.5M | +123.2% |
| FY2018 | $48.6M | -55.2% |
| FY2017 | $108.5M | +123.2% |
| FY2016 | $48.6M | +30.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026